HPV & HPV vaccination: Issues in developing countries

Indian Journal of Medical Research

Volumn 130, Issue 3, 2009, Pages 327-333

  Bharadwaj, Mausumi ^a   Hussain, Showket ^b   Nasare, Vilas ^a   Das, Bhudev C ^b,c  

^a NATIONAL CENTRE FOR MEDIUM RANGE WEATHER FORECASTING   (India)

^b INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

^c UNIVERSITY OF DELHI   (India)

Author keywords

Cervical cancer; Human papillomavirus (HPV); Issues in india; Prophylactic vaccines; Therapeutic vaccines

Indexed keywords

DNA VACCINE; PLASMID DNA; WART VIRUS VACCINE;

CANCER MORTALITY; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; CULTURAL FACTOR; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INDIA; INFLUENZA; MALARIA; MEDICAL EDUCATION; MEDICAL ETHICS; RECOMMENDED DRUG DOSE; REVIEW; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS INFECTION; WART VIRUS;

DEVELOPING COUNTRIES; FEMALE; HUMANS; INDIA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 72649083677     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Perkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55: 74-108.
2. National Cancer Registry Project (NCRP) Biennial Report 2001. New Delhi: Indian Council of Medical Research; 2001.
3. Das BC, Gopalkrishna V, Hedau S, Katiyar S. Cancer of the uterine cervix and human papillomavirus infection. Curr Sci 2000; 77: 101-11.
4. Munoz N, Bosch Fx, de Sanjose S, Herrero R, Castellsague x, Shah KV, et al. Epidemiological classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
5. zur Hausen H. Viruses in human cancers. Science 1991; 254: 1167-73.
6. Bosch Fx. Epidemiology of human papillomavirus infections: new options for cervical cancer prevention. Salud Publica Mex 2003; 45 (Suppl 3): S326-39.
7. de Villers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324: 17-27.
8. Das BC, Sharma JK, Gopalkrishna V, Das DK, Singh V, Gissman L, et al. A high frequency of human papillomavirus DNA sequences in cervical carcinomas of Indian women as revealed by Southern blot hybridization and polymerase chain reaction. J Med Virol 1992; 36: 239-45.
9. Kailash U, Soundararajan CC, Lakshmy R, Arora R, Vivekanandhan S, et al. Telomerase activity as an adjunct to high-risk human papillomavirus types 16 and 18 and cytology screening in cervical cancer. Br J Cancer 2006; 95: 1250-7.
10. Kohaar I, Thakur N, Salhan S, Batra S, Singh V, Sharma A, et al. TNFα -308 G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cellular Oncol 2007; 29: 249-56.
11. Franceschi S, Rajkumar T, Vaccarella S, Gajalakshmi V, Sharmila A, Snijders PJ, et al. Human papillomavirus and risk factors for cervical cancer in Chennai, in India: a case control study. Int J Cancer 2003; 107: 127-213.
12. Sowjanya AP, Jain M, Poli UR. Prevalence and distribution of high-risk human papillomavirus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India. BMC Infect Dis 2005; 5: 116-22.
13. Das BC, Gopalkrishna V, Das DK, Sharma JK, Singh V, Luthra UK. Human papillomavirus DNA sequences in adenocarcinoma of the uterine cervix in Indian women. Cancer 1993; 72: 147-53.
14. Iwasawa A, Nieminen P, Lehtinen M, Paavonen J. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer 1996; 77: 2275-9.
15. Das BC, Hussain S, Nasare V, Bharadwaj M. Prospects and prejudices of human papillomavirus vaccines in India. Vaccine 2008; 26: 2669-79.
16. Villa LL, Costa RL, Pettac A, Andrade RP, Ault KA, Guiliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8.
17. Villa LL, Ault KA, Guiliano AR, Costa RL, Pettac A, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006; 24: 5571-83.
18. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-65.
19. Harper DM, Franco EL, Wheeler C, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4. 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
20. Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus- like particle vaccine through 5 years follow-up. Br J Cancer 2007; 6: 1459-66.
21. Crum C, Jones C, Kirkpatrick P. Fresh from the pipeline: Quadrivalent human papillomavirus recombinant vaccine. Nat Rev Drug Discov 2006; 5: 629-30.
22. Gardasil (quadrivalent human papillomavirus [types 6, 11, 16, 18] recombinant vaccine)[product monograph]. Kirkland (QC): Merck Frost Canada Ltd.; 2006.
23. Stanley M. Prophylactic HPV vaccines: prospects for eliminating anogenital cancer. Br J Cancer 2007; 96: 1320-3.
24. Joura EA, Leodolter S, Hernandez-Avila M, wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomized clinical trials. Lancet 2007; 369: 1693-702.
25. Stanley M. Immune responses to human papillomavirus. Vaccine 2006; 24 (Suppl): S16-S22.
26. Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, et al. Saftey and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007; 26: 201-9.
27. Available from: http://www. cdc. gov/mmwr/preview/mmwrhtml/ mm5740a2. htm.
28. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92: 11553-7.
29. Trottiesr H, Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics 2009; 12: 291-307.
30. Tindle RW, Frazer IH. Immune response to human papillomaviruses and the prospects for human papillomavirus- specific immunization. Curr Top Microbiol Immunol 1994; 186: 217-53.
31. Frazer IH, Quinn M, Nicklin JL, Tan J, Perrin LC, Ng P, et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIx adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004; 23: 172-81.
32. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, et al. A phase I trial of a Human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000; 6: 3406-16.
33. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004; 4: 46-55.
34. Leggatt GR, Frazer IH. HPV vaccines: the beginning of the end for cervical cancer. Curr Opin Immunol 2007; 19: 232-8.
35. Greenstone HL, Nieland JD, DeVisser KE, De Bruijn ML, Kirnbauer R, Roden RB, et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV 16 tumor model. Proc Natl Acad Sci USA 1998; 95:1800-5.
36. de Jong A, O'Neil T, Khan AY, Kwappenberg KM, Chisholm SE, Whittle NR et al. Enhancement of human papillomavirus (HPV) type 16, E6 and E7-specific T -cell immunity in healthy volunteers through vaccination with TA- CIN, an HPV L2E7E6 fusion protein vaccine. Vaccine 2002; 20: 3456-64.
37. Bharadwaj M, Mirowsky K, Botten J, Masten B,Yee J, Hjelle B. Genetic vaccines protect against Sin Nombre hantavirus challenge in the deer mouse (Peromyscus maniculatus). J Gen Virol 2002; 83: 1745-51.
38. Bharadwaj M, Lyons CR, Wortman IA, Hjelle B. Intramuscular inoculation of Sin Nombre hantavirus cDNAs induces cellular and humoral immune responses in BALB/c mice. Vaccine 1999; 17: 2836-43.
39. Srivastava IK, Liu MA. Gene vaccines. Ann Intern Med 2003; 138: 550-9.
40. Donnelly JJ, Ulmer JB, Liu MA. Immunization with DNA. J Immunol Methods 1994; 176: 145-52.
41. Ivory C, Chadee K. DNA vaccines: designing strategies against parasitic infections. Genetic Vaccines Ther 2004; 2: 17-24.
42. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178: 92-100.
43. Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000; 18: 1893-901.
44. Conry R, LoBuglio A, Loechel F, Moore SE, Sumerel LA, Barlow DL, et al. A carcinoembryonic antigen polynucleotide vaccine for human clinical use. Cancer Gene Ther 1995; 2: 33-8.
45. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87: 982-90.
46. Schleiss MR, Heineman TC. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 2005; 4: 381-6.
47. Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol 2005; 175: 633-9.
48. Haile M, Kallenius G. Recent developments in tuberculosis vaccines. Curr Opin Infect Dis 2005; 18: 211-5.
49. Wang R, Richie TL, Baraceros MF, Rahardjo N, Gay T, Banania JG, et al. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect Immune 2005; 73: 2863-72.
50. U. S. Newswire: Releases: CDC, Fort Dodge Animal Health Achieve First Licensed DNA Vaccine; Collaboratior Technology to Protect Horses from West Nile Viruses dated 18/7/2005.
51. Rocha-Zavaleta L, Alejandre JE, Garcia-carranca A. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16- L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses. J Med Virol 2002; 66: 86-95.
52. Leder C, Kleinschmidt JA, Wiethe C, Muller M. Enhancement of capsid gene expression: preparing the human papillomavirus type16 major structural gene L1 for DNA vaccination purposes. J Virol 2001; 75: 9201-9.
53. Sheets EE, Urban RG, Crum CP, Hedley ML, Politch JA, Gold MA, et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 2003; 188: 916-26.
54. Huang C-H, Monie A, Alvarez RD, Wu T. -C. DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med 2007; 39: 679-89.
55. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchand CD, et al. Comparison of the immuno genicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6,11,16,18) L1 virus like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 188: 2135-45.
56. Goldie S. A public health approach to cervical cancer control: considerations of screening and vaccination strategies. Int J Gynecol Obstet 2006; 94: S95-S105.
57. Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccine: underlying mechanisms. Vaccine 2006; 24 (Suppl 3): 106-13.
58. TM - a bivalent L1 virus like particle vaccine for prevention of Human Papillomavirus type 16-and 18-associated cervical cancer. Expert Opin Biol Ther 2007; 7: 391-6.
59. Agurto I, Arrossi S, White S, Coffey P, Dzuba I, Bingham A, et al. Involving the community in cervical cancer prevention programs. Int J Gynecol Obstet 2005; 89 (Suppl 2): S38-S45.
60. Blumenthal PD, Lauterbach M, Seller JW, Sankaranarayanan R. Training for cervical cancer prevention programs in low- resource settings: focus on visual inspection with acetic acid and cryotherapy. Int J Gynecol Obstet 2005; 89 (Suppl 2): S30-7.
61. Jacob M, Bradley J, Barone MA. Human Papillomavirus vaccines: what does the future hold for preventing cervical cancer in resource-poor settings through immunization programs? Sex Transm Dis 2005; 32: 6352-640.